Dec 2018 APPIRED III
APPIRED III study is getting well on its way with 6 centres started with including patients. These centres are Singapore NUH, CZE Eindhoven, Jessa, Hasselt, UniMed Wien Vienna, Almazov Heart…
Clinical Data APPIRED I and APPIRED II are basis for breakthrough
Computational model clarifies immune response during cardiac surgery 11 October 2018 A research team led by Peter Sloot, professor of Complex Adaptive Systems at the UvA, has managed to pinpoint…
Approval for Solid Organ Transplantation Study
Approval has been obtained in October 2018 to start with a solid organ transplantation study with RESCAP platform technology under supervision of PI Dr Joost van der Heijden from Vumc…
Sister Company AMRIF readying up for clinical trial in chronic inflammatory disease
AMRIF, Alloksys’s sister company is readying up for trials in several chronic inflammatory disease applications. First of these are a study in RA patients, based on excellent results with hRESCAP…
APPIRED III started recruitment in Asia at NUHCS, Singapore
Following the start of patient inclusion in Europe, the first Asian center participating international study APPIRED lll has started patient recruitment. The National University Heart Centre, Singapore (NUHCS) is the…
APPIRED III clinical study kicked off with first patient recruited
Wageningen, 16 November 2017- Alloksys Life Sciences announced today that its international APPIRED lll clinical study has started with inclusion of the first patient in Eindhoven, the Netherlands. Patients undergoing…
Alloksys announces new Supervisory Board member, Kevin Driscoll
Wageningen, 23 October 2017- Alloksys Life Sciences announced today that Kevin Driscoll has been appointed to its Supervisory Board. Dr. Driscoll is a proven Healthcare executive with 30 years experience…
- 1
- 2